Published on June 22, 2012Gentris® Corporation (www.gentris.com), a
global leader in the application of genomic biomarkers to clinical studies,
announced today that it has signed a Memorandum of Understanding with the
Shanghai Institutes of Preventative Medicine to advance global personalized
medicine. The goal of this USA-China collaboration is to create translational
research and epidemiological projects, as well as training and education
programs, focused on pharmacogenomics and clinical sample banking, which will
drive innovation in drug development and improvements in patient care.Through
this collaboration, Gentris and the Shanghai Institutes of Preventative
Medicine will work together to launch cutting-edge research projects to
discover, develop, and validate new genomic biomarkers. Gentris will take the
lead to identify sponsors in the United States , e.g., pharmaceutical
companies, for these personalized medicine projects while the Shanghai
Institutes of Preventative Medicine will seek support from Chinese
organizations.The tuberculosis drug-induced liver injury pilot (TB DILI Study),
conducted between Gentris, the Shanghai Institutes of Preventative Medicine,
and a non-profit research institute in Research Triangle Park (RTP) serves as a
model for USA-China collaborations. In this study, investigators designed a
common protocol and pooled their resources to investigate DILI among
tuberculosis patients in three Shanghai
hospitals. By utilizing metabolomics and pharmacogenomics, they are evaluating biomarkers
for early detection. Dr. Tong Zhou, Senior Director of China Initiatives for
Gentris, is Co-Principal Investigator for the TB DILI Study and has significant
experience in developing and managing collaborations between the United States and China . Dr. Zhou has also drawn upon
his extensive network in China
to begin establishing a satellite laboratory for Gentris in Shanghai
that complies with U.S.
regulatory standards.Dr. Wu Fan, Director General of the Shanghai Institutes of
Preventative Medicine and the Shanghai
Municipal Center
for Disease Control and Prevention (Shanghai CDC),and Dr. Howard McLeod from
the University of
North Carolina will
provide strategic scientific oversight for personalized medicine
collaborations. Director Wu is recognized internationally as a leader in public
health initiatives. Dr. McLeod, Chief Scientific Advisor for Gentris, has been
involved in numerous global initiatives including the Pharmacogenetics for
Every Nation Initiative (PGENI), which he founded. It is anticipated that
combining the resources and expertise of a research institute, academic
institution, and industry—in both the United
States and China —will lead to more rapid
improvements in drug development and public health.
No comments:
Post a Comment